Search

Bringing focus to unmet needs in biliary tract and pancreatic cancer with the Brightline-2 Trial

Brightline-2 clinical trial is studying our investigational MDM2-p53 antagonist for people with advanced cancer in the biliary tract or pancreatic cancer.

Generalized pustular psoriasis (GPP): Unmet needs, the reality of living with the condition, and future management

Dr Emmanuelle Clerisme-Beaty, Boehringer Ingelheim’s Therapeutic Area Inflammation Head of Medicine, in conversation with Dr Bruce Strober MD, PhD

infographic_unmet_needs_in_gpp.pdf

Innovation in Immunology | Human Health | Boehringer Ingelheim US

BI's Immunology & Respiratory research combines our ability to address unmet medical needs with pioneering patient-centered approaches.

We support non-linear career paths.

Emmanuelle Clerisme-Beaty talks about making breakthroughs in the rare disease space.“I’m here to let patients know that they're not alone”

FDA Grants Fast Track to Jardiance® (empagliflozin) for CKD | Boehringer Ingelheim US

The FDA has granted Fast Track designation for JARDIANCE to reduce risk of disease progression and CV death with CKD. View ISI, PI & Med Guide.

Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

More Health Overview

Working at the intersection of human and animal health, we have unique opportunities to positively impact vulnerable populations.

US FDA grants Fast Track designation to Jardiance® (empagliflozin) to improve outcomes following a heart attack

FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease

Translating Human Pharma Science into Animal Health Innovation

Megan Grether shares her perspectives on the importance of translating human pharma science to accelerate innovation in animal health

First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline

FDA accepts sNDA for children/adolescents with fibrosing ILD

U.S. FDA accepts sNDA for OFEV® (nintedanib) for the potential treatment of children and adolescents aged 6-17 with fibrosing interstitial lung disease

Spesolimab prevented generalized pustular psoriasis flares in Effisayil™ 2 trial

Asthmatic Horse's First Inhaled Therapy | Boehringer Ingelheim US

Click here to read about Boehringer Ingelheim launching the first inhaled therapy for horses suffering with severe asthma in the United States.

Jardiance® (empagliflozin) Meets Endpoint Reducing CV Death | BI US

BI announces results from the EMPEROR-Reduced trial with heart failure with reduced ejection fraction, with & without diabetes. View ISI, PI and Med Guide.

Exploring beyond boundaries for innovation in animal health

Exploring beyond boundaries by partnering with human pharma and animal health may hold the key to accelerating innovation in animal health.

Phase III study showed Ofev® slows the loss of pulmonary function in people living with systemic sclerosis associated ILD

Phase III study showed Ofev slows the loss of pulmonary function in people living with systemic sclerosis associated ILD

Parasiticides

FIBRONEER™ trials for IPF, other progressive fibrosing ILDs

Donald Zoz, M.D., Director and Senior Clinical Program Leader for Pulmonary Fibrosis, discusses the FIBRONEER™ global clinical program

Boehringer Ingelheim announces InPedILD PhaseIII trial results

Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center

Innovation in CardioMetabolic Disease Research

Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers